Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Threonine synthase-like 2 (THNSL2) is a human enzyme encoded by the THNSL2 gene. It acts as a catabolic phospho-lyase, degrading O-phospho-threonine and structurally related substrates to produce alpha-ketobutyrate, phosphate, and ammonia. In mouse, an alternatively spliced form has been shown to function as a cytokine called SOFAT (secreted osteoclastogenic factor of activated T cells), promoting IL-6 production in osteoblasts and potentially modulating inflammatory responses. While multiple transcript variants exist and some functional data come from animal studies, the principal characterized activity in humans is enzyme-based amino acid catabolism. There are currently no approved therapeutic drugs targeting this protein, and its direct role in human pathophysiology or as a drug target remains undetermined.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Threonine synthase-like 2 (THNSL2).